Cargando…
Nucleoporin Nup155 is part of the p53 network in liver cancer
Cancer-relevant signalling pathways rely on bidirectional nucleocytoplasmic transport events through the nuclear pore complex (NPC). However, mechanisms by which individual NPC components (Nups) participate in the regulation of these pathways remain poorly understood. We discover by integrating larg...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517424/ https://www.ncbi.nlm.nih.gov/pubmed/31089132 http://dx.doi.org/10.1038/s41467-019-10133-z |
_version_ | 1783418274110767104 |
---|---|
author | Holzer, Kerstin Ori, Alessandro Cooke, Amy Dauch, Daniel Drucker, Elisabeth Riemenschneider, Philip Andres-Pons, Amparo DiGuilio, Amanda L. Mackmull, Marie-Therese Baßler, Jochen Roessler, Stephanie Breuhahn, Kai Zender, Lars Glavy, Joseph S. Dombrowski, Frank Hurt, Ed Schirmacher, Peter Beck, Martin Singer, Stephan |
author_facet | Holzer, Kerstin Ori, Alessandro Cooke, Amy Dauch, Daniel Drucker, Elisabeth Riemenschneider, Philip Andres-Pons, Amparo DiGuilio, Amanda L. Mackmull, Marie-Therese Baßler, Jochen Roessler, Stephanie Breuhahn, Kai Zender, Lars Glavy, Joseph S. Dombrowski, Frank Hurt, Ed Schirmacher, Peter Beck, Martin Singer, Stephan |
author_sort | Holzer, Kerstin |
collection | PubMed |
description | Cancer-relevant signalling pathways rely on bidirectional nucleocytoplasmic transport events through the nuclear pore complex (NPC). However, mechanisms by which individual NPC components (Nups) participate in the regulation of these pathways remain poorly understood. We discover by integrating large scale proteomics, polysome fractionation and a focused RNAi approach that Nup155 controls mRNA translation of p21 (CDKN1A), a key mediator of the p53 response. The underlying mechanism involves transcriptional regulation of the putative tRNA and rRNA methyltransferase FTSJ1 by Nup155. Furthermore, we observe that Nup155 and FTSJ1 are p53 repression targets and accordingly find a correlation between the p53 status, Nup155 and FTSJ1 expression in murine and human hepatocellular carcinoma. Our data suggest an unanticipated regulatory network linking translational control by and repression of a structural NPC component modulating the p53 pathway through its effectors. |
format | Online Article Text |
id | pubmed-6517424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65174242019-05-16 Nucleoporin Nup155 is part of the p53 network in liver cancer Holzer, Kerstin Ori, Alessandro Cooke, Amy Dauch, Daniel Drucker, Elisabeth Riemenschneider, Philip Andres-Pons, Amparo DiGuilio, Amanda L. Mackmull, Marie-Therese Baßler, Jochen Roessler, Stephanie Breuhahn, Kai Zender, Lars Glavy, Joseph S. Dombrowski, Frank Hurt, Ed Schirmacher, Peter Beck, Martin Singer, Stephan Nat Commun Article Cancer-relevant signalling pathways rely on bidirectional nucleocytoplasmic transport events through the nuclear pore complex (NPC). However, mechanisms by which individual NPC components (Nups) participate in the regulation of these pathways remain poorly understood. We discover by integrating large scale proteomics, polysome fractionation and a focused RNAi approach that Nup155 controls mRNA translation of p21 (CDKN1A), a key mediator of the p53 response. The underlying mechanism involves transcriptional regulation of the putative tRNA and rRNA methyltransferase FTSJ1 by Nup155. Furthermore, we observe that Nup155 and FTSJ1 are p53 repression targets and accordingly find a correlation between the p53 status, Nup155 and FTSJ1 expression in murine and human hepatocellular carcinoma. Our data suggest an unanticipated regulatory network linking translational control by and repression of a structural NPC component modulating the p53 pathway through its effectors. Nature Publishing Group UK 2019-05-14 /pmc/articles/PMC6517424/ /pubmed/31089132 http://dx.doi.org/10.1038/s41467-019-10133-z Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Holzer, Kerstin Ori, Alessandro Cooke, Amy Dauch, Daniel Drucker, Elisabeth Riemenschneider, Philip Andres-Pons, Amparo DiGuilio, Amanda L. Mackmull, Marie-Therese Baßler, Jochen Roessler, Stephanie Breuhahn, Kai Zender, Lars Glavy, Joseph S. Dombrowski, Frank Hurt, Ed Schirmacher, Peter Beck, Martin Singer, Stephan Nucleoporin Nup155 is part of the p53 network in liver cancer |
title | Nucleoporin Nup155 is part of the p53 network in liver cancer |
title_full | Nucleoporin Nup155 is part of the p53 network in liver cancer |
title_fullStr | Nucleoporin Nup155 is part of the p53 network in liver cancer |
title_full_unstemmed | Nucleoporin Nup155 is part of the p53 network in liver cancer |
title_short | Nucleoporin Nup155 is part of the p53 network in liver cancer |
title_sort | nucleoporin nup155 is part of the p53 network in liver cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517424/ https://www.ncbi.nlm.nih.gov/pubmed/31089132 http://dx.doi.org/10.1038/s41467-019-10133-z |
work_keys_str_mv | AT holzerkerstin nucleoporinnup155ispartofthep53networkinlivercancer AT orialessandro nucleoporinnup155ispartofthep53networkinlivercancer AT cookeamy nucleoporinnup155ispartofthep53networkinlivercancer AT dauchdaniel nucleoporinnup155ispartofthep53networkinlivercancer AT druckerelisabeth nucleoporinnup155ispartofthep53networkinlivercancer AT riemenschneiderphilip nucleoporinnup155ispartofthep53networkinlivercancer AT andresponsamparo nucleoporinnup155ispartofthep53networkinlivercancer AT diguilioamandal nucleoporinnup155ispartofthep53networkinlivercancer AT mackmullmarietherese nucleoporinnup155ispartofthep53networkinlivercancer AT baßlerjochen nucleoporinnup155ispartofthep53networkinlivercancer AT roesslerstephanie nucleoporinnup155ispartofthep53networkinlivercancer AT breuhahnkai nucleoporinnup155ispartofthep53networkinlivercancer AT zenderlars nucleoporinnup155ispartofthep53networkinlivercancer AT glavyjosephs nucleoporinnup155ispartofthep53networkinlivercancer AT dombrowskifrank nucleoporinnup155ispartofthep53networkinlivercancer AT hurted nucleoporinnup155ispartofthep53networkinlivercancer AT schirmacherpeter nucleoporinnup155ispartofthep53networkinlivercancer AT beckmartin nucleoporinnup155ispartofthep53networkinlivercancer AT singerstephan nucleoporinnup155ispartofthep53networkinlivercancer |